Healthcare Professionals

  • Email
  • Help

Information for you

On this page, you will find information on the Agency’s activities that are most relevant to healthcare professionals, including news, and events.

You can contribute to the Agency’s work by responding to public consultations

Learn more about how Healthcare Professionals are actively involved in the work of the Agency.

Featured information

  • bacteria

    Antimicrobial resistance: information session

    On 19 September, EMA’s patients and consumers and healthcare professionals working parties attended an information session to raise awareness of the work of European Union institutions and agencies, Member States and World Health Organization in the fight against antimicrobial resistance. The meeting stimulated an exchange of ideas on improving communication, education and training. The presentations and recording of the session are available.

  • public_hearing_report

    Public hearing at EMA

    Patients, carers, doctors, pharmacists and academics shared their experiences with valproate, a medicine currently prescribed for epilepsy, bipolar disorder and migraine, at EMA’s public hearing on 26 September 2017. 65 people attended including 28 patients and patient representatives, 19 healthcare professionals and academics, 11 attendees from pharmaceutical industry and 7 from media. There were 25 speaker contributions,grouped into 16 speaker slots. The European Parliament representative concluded that the hearing was a positive experience. A summary report is available.

  • Joint meeting of patients and consumers and healthcare professionals working parties

    EMA held a joint meeting of the Patients' and Consumers' Working Party (PCWP) and the Healthcare Professionals' Working Party (HCPWP) on 20 September. Topics included work plans for 2018-19, proposed revision of their mandates and rules of procedure, streamlining the eligibility status re-assessment processes, compassionate use of medicines, EMA preparedness for Brexit, EMA’s first public hearing and next steps following the European Commission report on product information. All presentations are available.

  • biosimilars

    Biosimilar medicines

    EMA and the European Commission have published an information guide for healthcare professionals on the science and regulation underpinning the use of biosimilar medicines. EU scientific experts and organisations representing doctors, nurses, pharmacists and patients contributed to the development of this guide.

News for healthcare professionals

Events of interest

  • 07/07/2017

    EMA

    Multiple sclerosis workshop - Registries initiative

    The EMA’s initiative for patient registries explores ways of expanding the use of patient registries in the benefit-risk evaluation of medicines within the European Economic Area. The participants of the workshop on Multiple sclerosis registries included representatives from the European MS Platform (EMSP) and its EUReMS group, the “Big MS Data” group, national MS registries, marketing authorisation holders, health technology assessment and reimbursement bodies, patients, national competent authorities, and the EMA. The workshop objectives were to agree on implementable recommendations on the core data elements to be collected in registries, protocols, consents, governance and registry interoperability and on the actions needed from the stakeholder groups to advance registry use in supporting regulatory benefit-risk evaluations. ... Read more

  • 14/06/2017

    EMA

    Cystic fibrosis workshop - Registries initiative

    The EMA’s initiative for patient registries explores ways of expanding the use of patient registries in the benefit-risk evaluation of medicines within the European Economic Area. The participants of the workshop on cystic fibrosis registries included representatives from the European CF Society Patient Registry, national CF registries, marketing authorisation holders, health technology assessment, national competent authorities, and the EMA. The workshop objectives were to agree on implementable recommendations on the core data elements to be collected in registries, protocols, consents, governance and registry interoperability and on the actions needed from the stakeholder groups to advance registry use in supporting regulatory benefit-risk evaluations. ... Read more

  • 19/09/2017

    EMA

    European Medicines Agency - Payer Community meeting

    The European Medicines Agency and European Union healthcare payers met to explore synergies and foster mutual understanding and cooperation to help improve timely and affordable access for patients to new medicinal products. The meeting aimed to be complementary to EMA's existing cooperation with Health Technology Assessment (HTA) bodies and especially with EUnetHTA. ... Read more

  • 19/09/2017

    EMA

    EMA Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting: info session on antimicrobial resistance

    The joint Patients' and Consumers' Working Party (PCWP) / Healthcare Professionals' Working Party (HCPWP) meeting on antimicrobial resistance aims to raise awareness of the work of European Union institutions, Member States and World Health Organization in the fight against antimicrobial resistance. It will also explain how the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control can support the European- and global-level fight against antimicrobial resistance. The meeting will also stimulate an exchange of ideas with patients and consumer and healthcare professional organisations on how to join efforts for improving communication, education and training in the fight against antimicrobial resistance. ... Read more

  • 16/10/2017 - 17/10/2017

    Joint Drug Information Association (DIA) / European Forum for Good Clinical Practice (EFGCP) /European Medicines Agency (EMA) conference on how to optimise children's access to innovative medicines

    The 2017 DIA/EFGCP/EMA Annual Paediatric Conference focuses on how to optimise children’s access to new medicines. With more than 10 years of the EU Paediatric Regulation, all stakeholders involved in paediatric drug development have seen progress in developing new medicines for children. This conference explores how to build on the successes from the past 10 years of EU Paediatric Regulation, and how to overcome challenges that still exist. The objectives of this year's conference include: - To update participants on current paediatric regulatory requirements, scientific and operational success and challenges; - To exchange experiences with regulatory authorities, academia and industry when developing medicines for children globally; - To discuss visions, daily challenges and potential ways to move forward and further improve processes for paediatric drug development. The registration form is included in the published agenda. ... Read more

  • See all Events of interest

Information for:

Find information for...

FAQ spotlight